Cargando…

Comorbidity and diagnosis distribution in transdiagnostic treatments for emotional disorders: A systematic review of randomized controlled trials

The advantages of transdiagnostic protocols for emotional disorders (ED) (anxiety and depression) include the ability to treat multiple psychological disorders using the same treatment protocol, and the capacity to better address comorbidity. Comorbidity in ED has been associated with higher rates o...

Descripción completa

Detalles Bibliográficos
Autores principales: González-Robles, Alberto, Díaz-García, Amanda, Miguel, Clara, García-Palacios, Azucena, Botella, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237379/
https://www.ncbi.nlm.nih.gov/pubmed/30440020
http://dx.doi.org/10.1371/journal.pone.0207396
_version_ 1783371184598941696
author González-Robles, Alberto
Díaz-García, Amanda
Miguel, Clara
García-Palacios, Azucena
Botella, Cristina
author_facet González-Robles, Alberto
Díaz-García, Amanda
Miguel, Clara
García-Palacios, Azucena
Botella, Cristina
author_sort González-Robles, Alberto
collection PubMed
description The advantages of transdiagnostic protocols for emotional disorders (ED) (anxiety and depression) include the ability to treat multiple psychological disorders using the same treatment protocol, and the capacity to better address comorbidity. Comorbidity in ED has been associated with higher rates of severity, functional impairment, and chronicity. However, no attempts have been made in the literature to systematically review whether these studies include assessments to evaluate the treatment response in comorbid diagnoses, in addition to the principal diagnosis. Moreover, transdiagnostic treatments have been developed for a range of ED, but to date no study has analyzed the real distribution of diagnoses in these studies. The current study aimed to analyze: a) whether treatment response in comorbidity is evaluated in transdiagnostic treatments for ED; b) what diagnoses are targeted in transdiagnostic treatments for ED; and c) the real distribution of the diagnoses at baseline in these studies. A systematic search of the literature was conducted in PsycINFO, PubMed, EMBASE, and the Cochrane Library. Fifty-two randomized controlled trials were identified, with a total of 7007 adult participants. The results showed that, although most of the studies reported data on comorbidity at baseline, only 40% of them examined the effects of the intervention on the comorbid disorders. The most commonly targeted diagnoses in transdiagnostic protocols were panic/agoraphobia, generalized anxiety, social anxiety, and depression. Other disorders, such as obsessive-compulsive disorder, posttraumatic stress disorder, and anxiety/depression not otherwise specified, were marginally included in these studies. Regarding the distribution of diagnoses at baseline, generalized anxiety, panic/agoraphobia, social anxiety, and depression were the most frequently observed, whereas depression not otherwise specified was the least represented. The results highlight the importance of assessing comorbidity in addition to the principal diagnoses in transdiagnostic treatments, in order to draw conclusions about the true potential of these interventions to improve comorbid symptoms. Implications of the current study and directions for future research are discussed.
format Online
Article
Text
id pubmed-6237379
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-62373792018-12-01 Comorbidity and diagnosis distribution in transdiagnostic treatments for emotional disorders: A systematic review of randomized controlled trials González-Robles, Alberto Díaz-García, Amanda Miguel, Clara García-Palacios, Azucena Botella, Cristina PLoS One Research Article The advantages of transdiagnostic protocols for emotional disorders (ED) (anxiety and depression) include the ability to treat multiple psychological disorders using the same treatment protocol, and the capacity to better address comorbidity. Comorbidity in ED has been associated with higher rates of severity, functional impairment, and chronicity. However, no attempts have been made in the literature to systematically review whether these studies include assessments to evaluate the treatment response in comorbid diagnoses, in addition to the principal diagnosis. Moreover, transdiagnostic treatments have been developed for a range of ED, but to date no study has analyzed the real distribution of diagnoses in these studies. The current study aimed to analyze: a) whether treatment response in comorbidity is evaluated in transdiagnostic treatments for ED; b) what diagnoses are targeted in transdiagnostic treatments for ED; and c) the real distribution of the diagnoses at baseline in these studies. A systematic search of the literature was conducted in PsycINFO, PubMed, EMBASE, and the Cochrane Library. Fifty-two randomized controlled trials were identified, with a total of 7007 adult participants. The results showed that, although most of the studies reported data on comorbidity at baseline, only 40% of them examined the effects of the intervention on the comorbid disorders. The most commonly targeted diagnoses in transdiagnostic protocols were panic/agoraphobia, generalized anxiety, social anxiety, and depression. Other disorders, such as obsessive-compulsive disorder, posttraumatic stress disorder, and anxiety/depression not otherwise specified, were marginally included in these studies. Regarding the distribution of diagnoses at baseline, generalized anxiety, panic/agoraphobia, social anxiety, and depression were the most frequently observed, whereas depression not otherwise specified was the least represented. The results highlight the importance of assessing comorbidity in addition to the principal diagnoses in transdiagnostic treatments, in order to draw conclusions about the true potential of these interventions to improve comorbid symptoms. Implications of the current study and directions for future research are discussed. Public Library of Science 2018-11-15 /pmc/articles/PMC6237379/ /pubmed/30440020 http://dx.doi.org/10.1371/journal.pone.0207396 Text en © 2018 González-Robles et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
González-Robles, Alberto
Díaz-García, Amanda
Miguel, Clara
García-Palacios, Azucena
Botella, Cristina
Comorbidity and diagnosis distribution in transdiagnostic treatments for emotional disorders: A systematic review of randomized controlled trials
title Comorbidity and diagnosis distribution in transdiagnostic treatments for emotional disorders: A systematic review of randomized controlled trials
title_full Comorbidity and diagnosis distribution in transdiagnostic treatments for emotional disorders: A systematic review of randomized controlled trials
title_fullStr Comorbidity and diagnosis distribution in transdiagnostic treatments for emotional disorders: A systematic review of randomized controlled trials
title_full_unstemmed Comorbidity and diagnosis distribution in transdiagnostic treatments for emotional disorders: A systematic review of randomized controlled trials
title_short Comorbidity and diagnosis distribution in transdiagnostic treatments for emotional disorders: A systematic review of randomized controlled trials
title_sort comorbidity and diagnosis distribution in transdiagnostic treatments for emotional disorders: a systematic review of randomized controlled trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237379/
https://www.ncbi.nlm.nih.gov/pubmed/30440020
http://dx.doi.org/10.1371/journal.pone.0207396
work_keys_str_mv AT gonzalezroblesalberto comorbidityanddiagnosisdistributionintransdiagnostictreatmentsforemotionaldisordersasystematicreviewofrandomizedcontrolledtrials
AT diazgarciaamanda comorbidityanddiagnosisdistributionintransdiagnostictreatmentsforemotionaldisordersasystematicreviewofrandomizedcontrolledtrials
AT miguelclara comorbidityanddiagnosisdistributionintransdiagnostictreatmentsforemotionaldisordersasystematicreviewofrandomizedcontrolledtrials
AT garciapalaciosazucena comorbidityanddiagnosisdistributionintransdiagnostictreatmentsforemotionaldisordersasystematicreviewofrandomizedcontrolledtrials
AT botellacristina comorbidityanddiagnosisdistributionintransdiagnostictreatmentsforemotionaldisordersasystematicreviewofrandomizedcontrolledtrials